Business Model Breakdown
How AVITA Medical Inc Makes Money
RCEL
Market Cap
$121M
Annual Revenue
$72M
Profit Margin
0.0%
The Short Version
AVITA Medical develops and commercializes the RECELL System, an innovative medical device that allows healthcare professionals to prepare a patient's own skin cells (autologous spray-on skin) at the point of care. This technology is used for treating severe burns, and more recently, for repigmenting stable vitiligo lesions. The company generates revenue by selling these single-use RECELL System devices directly to hospitals, burn centers, and dermatology clinics, enabling them to provide advanced regenerative medicine solutions.
Where the Revenue Comes From
Sales of RECELL System devices (~100% of revenue)
Who buys: Hospitals, burn centers, dermatologists, and other medical facilities/providers.
Why It Works (Competitive Advantages)
- ✔Proprietary RECELL System technology
- ✔FDA approvals for multiple indications (burns, vitiligo)
- ✔Demonstrated clinical efficacy in wound care and repigmentation
Economic Moat: Narrow (Intangible Assets/IP (RECELL patent protection and regulatory approvals), Switching Costs (for medical professionals trained on and integrated with RECELL system))
What Our Analysis Says
DVR Score as of April 6, 2026
AVITA Medical Inc. continues to present a compelling long-term opportunity, primarily driven by its RECELL System's expansion into the vitiligo market, which significantly enhances its Total Addressable Market (TAM). The proprietary nature of RECELL and its FDA approvals provide a strong competitive moat, and projected Q1 2026 revenue growth indicates positive commercialization momentum. However, the company remains unprofitable, as evidenced by negative EPS, and the recent S-3 shelf registration for up to $200M in potential equity offerings introduces a significant risk of future shareholder dilution, particularly for a company with a current market cap of $0.09B. While the underlying growth thesis remains robust, this financial overhang elevates the overall risk profile and impacts capital allocation concerns, warranting a score adjustment reflecting both the continued high potential and increased financial uncertainty.